A Multi-Centre Clinical Trial Evaluating the Efficacy and Safety of Alfaxan® Administered to Bitches for Induction of Anaesthesia Prior to Caesarean Section
World Small Animal Veterinary Association World Congress Proceedings, 2008
Steven Metcalfe1, BSc, BVMS(Hons), MSc, MACVSc; Amanda Hulands-Nave2; Michael Bell3; Christine Kidd4; Kirby Pasloske5; Brad O'Hagan5
1Applecross Veterinary Hospital, Applecross, WA, Australia; 2Bellarine Animal Practice, Newcomb, Victoria, Australia; 3Craigieburn Veterinary Hospital, Craigieburn, Victoria, Australia; 4Manly Road Veterinary Hospital, Manly West, Qld, Australia; 5Jurox Pty Ltd, Rutherford, NSW, Australia

Abstract

Not more than 400 words maximum, including figures). Use single line spacing. Line drawings, charts and graphs are suggested. Photographs, radiographs or ultrasound reproduction are not permitted. A clear indication must be given as to the position of any figure in the text. The box below will expand to take the text or figure but do not exceed 400 words.

Alfaxan® (Jurox Pty Ltd, Rutherford, NSW) is an injectable formulation of the neuroactive steroid anaesthetic drug alfaxalone (10 mg/mL). This investigation was designed to evaluate the efficacy and safety of Alfaxan® for induction of bitches prior to Caesarean section. The study was a prospective, multi-centre, positive-controlled, randomised efficacy study with two parallel groups: 1) Alfaxan® and, 2) Rapinovet X®--(propofol10 mg/mL). Animal Ethics Committee approval was obtained (No. JAEC/05/012).

A total of 74 bitches were induced intravenously to anaesthesia with 48 and 26 receiving Alfaxan® and Rapinovet X®, respectively. No premedicants were administered. All bitches were intubated and maintained on isoflurane and oxygen. Parameters were assessed prior to, during and after anaesthesia. The survival and vigour of pups delivered by Caesarean were also assessed. Parametric descriptive statistics, Student's T-tests, and linear or logistic regression were performed in Microsoft Excel or SAS for Windows, version 8.02 (SAS Institute Inc, Cary, NC, USA).

The average induction dose of Alfaxan® was 1.9 mg/kg body weight. Cardiovascular and respiratory parameters were well maintained during the induction, maintenance and recovery periods for both treatment groups. Immediate post induction apnoea occurred in 15% and 25% of Alfaxan® and Rapinovet X® cases, respectively. Anaesthetic induction was scored as: 1 (unacceptable), 2 (acceptable) or 3 (excellent). The average quality of anaesthesia was numerically superior during induction and anaesthesia with Alfaxan® compared to Rapinovet X®. Ninety-eight (98) and 81% of bitches scored a top score of 3 for induction and anaesthesia with Alfaxan®, respectively, while only 89 and 65% scored a 3 for the same parameters with Rapinovet X®. Anaesthetic recovery was scored as: 1 (poor), 2 (fair), 3 (good) and, 4 (excellent). Average scores for recovery were similar between the two treatment groups. No bitch fatalities were observed in this study. There were no statistically significant differences between treatment groups for the puppy variables; however, puppy vigour scores for Alfaxan® were numerically superior versus Rapinovet X®. Puppies born by Caesarean section to bitches having been administered Alfaxan® or Rapinovet X® had similar survival rates 24 hours after birth (i.e., 97 and 98%, respectively).

This study confirms the safety and efficacy of Alfaxan® for the purpose of anaesthetic induction for Caesarean section in the bitch.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Steven Metcalfe , BSc, BVMS(Hons), MSc, MACVSc
Applecross Veterinary Hospital
Applecross, WA , Australia


MAIN : Free Communications : Efficacy & Safety ofAlfaxan
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27